Last reviewed · How we verify
Bevacizumab maintenance therapy
Inhibits vascular endothelial growth factor A (VEGF-A)
Inhibits vascular endothelial growth factor A (VEGF-A) Used for Colorectal cancer, Breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | Bevacizumab maintenance therapy |
|---|---|
| Also known as | Avastin® (bevacizumab) |
| Sponsor | Sanofi |
| Drug class | Angiogenesis inhibitor |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bevacizumab is a recombinant humanized monoclonal antibody that binds to VEGF-A, preventing its interaction with its receptors and thereby inhibiting angiogenesis.
Approved indications
- Colorectal cancer
- Breast cancer
- Non-small cell lung cancer
Common side effects
- Hypertension
- Nausea
- Fatigue
Key clinical trials
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab maintenance therapy CI brief — competitive landscape report
- Bevacizumab maintenance therapy updates RSS · CI watch RSS
- Sanofi portfolio CI